A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
InfuSystem Holdings, Inc
INFU
$195M
Mkt Cap
$9.12
+2.59%
InfuSystem Holdings, Inc (INFU) has a current P/E ratio of 29.4, compared to its historical median P/E of 28.9. The stock is currently considered Fair based on its historical valuation range.
InfuSystem Holdings, Inc (INFU) has a 5-year average return on invested capital (ROIC) of 4.4%. This is below average and may indicate limited pricing power.
InfuSystem Holdings, Inc (INFU) has a market capitalization of $195M. It is classified as a small-cap stock.
InfuSystem Holdings, Inc (INFU) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.06%.
Based on historical P/E analysis, InfuSystem Holdings, Inc (INFU) appears fair. The current P/E of 29.4 is 2% above its historical median of 28.9. The estimated fair value CAGR (P/E method) is -20.0%.
InfuSystem Holdings, Inc (INFU) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
InfuSystem Holdings, Inc. ("we," "us," "our" or the "Company") is a Delaware corporation. Formed in 2005, the Company operates through its subsidiary InfuSystem, Inc., a Delaware corporation ("InfuSystem" or "ISI"). Business Concept and Strategy We are a leading national healthcare service provider, facilitating outpatient care for Durable Medical Equipment (DME) manufacturers and healthcare providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site healthcare providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of seven locations in the United States ("U.S.") and Canada. We provide our services under a two-platform model: Patient Services and Device Solutions. Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex DME and related services.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 143M | 143M | 135M | 126M | 110M | 102M |
| Net Income | 6.6M | 6.6M | 2.3M | 872K | 18K | 1.4M |
| EPS | $0.31 | $0.31 | $0.11 | $0.04 | $0.00 | $0.06 |
| Free Cash Flow | 24M | 24M | 19M | 10M | 17M | 17M |
| ROIC | 9.6% | 9.4% | 5.0% | 2.9% | 1.2% | 3.6% |
| Gross Margin | 56.0% | 56.0% | 52.2% | 50.2% | 55.1% | 57.2% |
| Debt/Equity | 0.40 | 0.40 | 0.49 | 0.67 | 0.77 | 0.76 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 12M | 12M | 6.9M | 4.1M | 1.7M | 2.8M |
| Operating Margin | 8.3% | 8.3% | 5.1% | 3.2% | 1.5% | 2.8% |
| ROE | 11.6% | 11.5% | 4.3% | 1.7% | 0.0% | 3.2% |
| Shares Outstanding | 21M | 21M | 21M | 22M | 21M | 24M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 66M | 71M | 70M | 71M | 67M | 81M | 97M | 102M | 110M | 126M | 135M | 143M | 143M |
| Gross Margin | 71.2% | 70.3% | 63.5% | 61.0% | 58.9% | 57.8% | 60.3% | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% | 56.0% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 20M | 24M | 25M | 25M | 25M | 29M | 35M | 41M | 44M | 45M | 51M | 57M | 57M |
| EBIT | 9.3M | 7.3M | 974K | -3.8M | 415K | 3.5M | 8.8M | 2.8M | 1.7M | 4.1M | 6.9M | 12M | 12M |
| Op. Margin | 14.0% | 10.3% | 1.4% | -5.4% | 0.6% | 4.3% | 9.1% | 2.8% | 1.5% | 3.2% | 5.1% | 8.3% | 8.3% |
| Net Income | 3.4M | 2.8M | -222K | -21M | -1.1M | 1.4M | 17M | 1.4M | 18K | 872K | 2.3M | 6.6M | 6.6M |
| Net Margin | 5.0% | 3.9% | -0.3% | -29.1% | -1.6% | 1.7% | 17.8% | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% | 4.6% |
| Non-Recurring | 2.5M | 3.0M | 1.2M | 2.7M | 1.3M | 1.5M | 3.6M | 2.5M | 2.2M | 2.9M | 2.3M | 3.3M | 3.3M |
| Returns on Capital | |||||||||||||
| ROIC | 8.0% | 6.8% | 1.2% | -5.6% | 0.8% | 5.6% | 13.4% | 3.6% | 1.2% | 2.9% | 5.0% | 9.4% | 9.6% |
| ROE | 7.5% | 5.8% | -0.4% | -50.7% | -4.3% | 6.4% | 54.9% | 3.2% | 0.0% | 1.7% | 4.3% | 11.5% | 11.6% |
| ROA | 4.3% | 3.2% | -0.2% | -25.1% | -1.6% | 1.9% | 19.7% | 1.5% | 0.0% | 0.9% | 2.3% | 6.5% | 6.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 7.3M | 7.1M | 7.9M | 7.7M | 11M | 14M | 20M | 18M | 18M | 11M | 20M | 24M | 24M |
| Free Cash Flow | 5.3M | 6.7M | 7.7M | 7.6M | 11M | 11M | 19M | 17M | 17M | 10M | 19M | 24M | 24M |
| Owner Earnings | 4.8M | 3.8M | 3.3M | 2.5M | 5.8M | 536K | 3.6M | -2.7M | 8.8M | 1.2M | 8.9M | 12M | 12M |
| CapEx | 2.0M | 314K | 168K | 104K | 281K | 2.9M | 1.1M | 980K | 982K | 1.0M | 1.1M | 560K | 560K |
| Maint. CapEx | 1.9M | 2.3M | 4.1M | 4.5M | 4.6M | 12M | 14M | 15M | 4.9M | 5.9M | 7.1M | 8.2M | 8.2M |
| Growth CapEx | 85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 1.9M | 2.3M | 4.1M | 4.5M | 4.6M | 12M | 14M | 15M | 4.9M | 5.9M | 7.1M | 8.2M | 8.2M |
| CapEx/OCF | 27.5% | 4.5% | 2.1% | 1.3% | 2.5% | 21.1% | 5.4% | 5.4% | 5.6% | 9.1% | 5.3% | 2.3% | 2.3% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 204K | 179K | 75K | 58K | 10M | 0 | 0 | 560K | 5.5M | 153K | 1.2M | 9.9M | 9.9M |
| Buyback Yield | 0.3% | 0.3% | 0.1% | N/A | 14.0% | N/A | N/A | 0.1% | 3.1% | 0.1% | 0.7% | 5.2% | 5.1% |
| Stock-Based Comp | 576K | 996K | 462K | 682K | 957K | 997K | 2.6M | 6.4M | 3.8M | 4.1M | 4.5M | 4.4M | 4.4M |
| Debt Repayment | 62M | 70M | 67M | 37M | 6.3M | 4.9M | 37M | 82M | 42M | 55M | 56M | 52M | 52M |
| Balance Sheet | |||||||||||||
| Net Debt | 25M | 28M | 28M | 25M | 29M | 40M | 33M | 37M | 37M | 35M | 28M | 20M | 20M |
| Cash & Equiv. | 515K | 818K | 3.4M | 3.5M | 4.3M | 2.6M | 9.6M | 186K | 165K | 231K | 527K | 3.2M | 3.2M |
| Long-Term Debt | 19M | 27M | 27M | 25M | 29M | 30M | 29M | 33M | 33M | 29M | 24M | 20M | 20M |
| Debt/Equity | 0.55 | 0.56 | 0.63 | 0.92 | 1.65 | 1.93 | 1.05 | 0.76 | 0.77 | 0.67 | 0.49 | 0.40 | 0.40 |
| Interest Coverage | 3.0 | 4.3 | 0.7 | -2.9 | 0.3 | 1.9 | 7.0 | 2.0 | 1.2 | 1.9 | 3.9 | 9.2 | 9.2 |
| Equity | 46M | 50M | 51M | 31M | 20M | 22M | 41M | 48M | 48M | 52M | 58M | 57M | 57M |
| Total Assets | 80M | 95M | 96M | 69M | 64M | 79M | 97M | 98M | 99M | 103M | 104M | 101M | 101M |
| Total Liabilities | 34M | 45M | 46M | 38M | 44M | 57M | 56M | 49M | 51M | 51M | 46M | 43M | 43M |
| Intangibles | 25M | 32M | 31M | 25M | 20M | 15M | 11M | 11M | 8.4M | 7.4M | 6.5M | 6.9M | 6.9M |
| Retained Earnings | -44M | -41M | -41M | -62M | -63M | -61M | -44M | -54M | -59M | -59M | -57M | -61M | -61M |
| Working Capital | 729K | 3.7M | 4.3M | 5.2M | 2.7M | -2.5M | 6.8M | 9.2M | 10M | 15M | 15M | 16M | 16M |
| Current Assets | 15M | 19M | 21M | 18M | 18M | 19M | 30M | 22M | 25M | 31M | 32M | 36M | 36M |
| Current Liabilities | 15M | 15M | 16M | 12M | 15M | 22M | 23M | 13M | 14M | 16M | 18M | 20M | 20M |
| Per Share Data | |||||||||||||
| EPS | 0.15 | 0.12 | -0.01 | -0.91 | -0.05 | 0.07 | 0.80 | 0.06 | 0.00 | 0.04 | 0.11 | 0.31 | 0.31 |
| Owner EPS | 0.21 | 0.16 | 0.15 | 0.11 | 0.27 | 0.03 | 0.17 | -0.11 | 0.42 | 0.06 | 0.42 | 0.56 | 0.56 |
| Book Value | 2.08 | 2.17 | 2.28 | 1.36 | 0.93 | 1.15 | 1.88 | 2.04 | 2.31 | 2.40 | 2.70 | 2.68 | 2.68 |
| Cash Flow/Share | 0.32 | 0.30 | 0.36 | 0.34 | 0.52 | 0.71 | 0.94 | 0.77 | 0.84 | 0.51 | 0.96 | 1.14 | 0.69 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 22.4M | 23.2M | 22.2M | 22.8M | 21.9M | 19.4M | 21.7M | 23.7M | 20.8M | 21.8M | 21.3M | 21.4M | 21.4M |
| Valuation | |||||||||||||
| P/E Ratio | 20.5 | 25.0 | N/A | N/A | N/A | 117.4 | 24.0 | 275.0 | N/A | 268.0 | 74.0 | 28.9 | 29.4 |
| P/FCF | 13.1 | 10.3 | 6.7 | 6.9 | 6.7 | 14.6 | 21.7 | 22.5 | 10.6 | 22.9 | 9.0 | 8.0 | 8.2 |
| EV/EBIT | 10.0 | 13.4 | 82.8 | N/A | 250.7 | 57.0 | 50.4 | 150.2 | 127.8 | 64.2 | 28.5 | 17.2 | 18.0 |
| Price/Book | 1.5 | 1.4 | 1.0 | 1.7 | 3.6 | 7.2 | 10.2 | 8.1 | 3.7 | 4.5 | 3.0 | 3.3 | 3.4 |
| Price/Sales | 1.0 | 1.0 | 0.9 | 0.7 | 1.0 | 1.2 | 2.7 | 4.1 | 1.9 | 1.7 | 1.2 | 1.1 | 1.4 |
| FCF Yield | 7.7% | 9.7% | 14.8% | 14.4% | 15.0% | 6.9% | 4.6% | 4.4% | 9.3% | 4.4% | 11.2% | 12.5% | 12.2% |
| Market Cap | 69M | 70M | 52M | 53M | 74M | 160M | 416M | 391M | 179M | 234M | 174M | 192M | 195M |
| Avg. Price | 2.83 | 2.91 | 2.85 | 2.04 | 2.96 | 5.18 | 12.06 | 17.79 | 9.64 | 9.57 | 7.77 | 7.69 | 9.12 |
| Year-End Price | 3.07 | 3.00 | 2.35 | 2.32 | 3.38 | 8.22 | 19.21 | 16.50 | 8.40 | 10.72 | 8.14 | 8.96 | 9.12 |
InfuSystem Holdings, Inc passes 3 of 9 quality checks, indicating weak fundamentals.
InfuSystem Holdings, Inc trades at 29.4x trailing earnings, compared to its 15-year median P/E of 28.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 7.7x vs a median of 9.8x. The company's 5-year average ROIC is 4.4% with a gross margin of 54.1%. Total shareholder yield (buybacks) is 5.1%. At current prices, the estimated annualized return to fair value is +3.0%.
InfuSystem Holdings, Inc (INFU) reported annual revenue of $143 million in its most recent fiscal year, based on SEC EDGAR filings.
InfuSystem Holdings, Inc (INFU) has a net profit margin of 4.6%. This is a modest margin.
InfuSystem Holdings, Inc (INFU) generated $24 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
InfuSystem Holdings, Inc (INFU) has a debt-to-equity ratio of 0.40. This indicates a conservatively financed balance sheet.
InfuSystem Holdings, Inc (INFU) reported earnings per share (EPS) of $0.31 in its most recent fiscal year.
InfuSystem Holdings, Inc (INFU) has a return on equity (ROE) of 11.5%. This indicates moderate shareholder returns.
InfuSystem Holdings, Inc (INFU) has a 5-year average gross margin of 54.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for InfuSystem Holdings, Inc (INFU), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
InfuSystem Holdings, Inc (INFU) has a book value per share of $2.68, based on its most recent annual SEC filing.